Posted in

Ontario reports record 4,456 new Covid cases … and OH OH! … South Africa variant maybe sorta “slips through Pfizer vaccine”

10:00 a.m.: Ontario is reporting a record 4,456 COVID-19 cases Sunday, with 21 deaths. The seven-day avg is up to a record 3,573 cases daily or 172 weekly per 100,000, and up to 16.0 deaths/day.

Labs report 56,378 completed tests and 7.7% positive, the most for a Sunday since 2020.


South African variant can ‘break through’ Pfizer vaccine: Israeli study

JERUSALEM — The coronavirus variant discovered in South Africa can “break through” Pfizer/BioNTech’s COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is low and the research has not been peer reviewed.


It appears that the AstraZeneca jab has a much lower efficacy rate than either Moderna, Janssen or Pfizer. But guess which one Canada seems to have the most of for the GTA? Yup AstraZeneca.

Thank that schmuck in Ottawa for subjecting you to Vaccine Roulette. And given we now live in Bananada I wonder who is getting the highest efficacy vaccines if indeed their ratings are reliable?

Official: Chinese vaccines’ effectiveness low

The effectiveness of a Sinovac vaccine at preventing symptomatic infections was found to be as low as 50.4% by researchers in Brazil, near the 50% threshold at which health experts say a vaccine is useful. By comparison, the Pfizer-BioNTech vaccine has been found to be 97% effective.

Related… Comparison of Vaccine efficacy of approved jabs in Canada –

The Pfizer and Moderna vaccines have the highest efficacy at around 95 per cent. Lower efficacy, in the 60 to 70 per cent range, was found for the AstraZeneca and Janssen products. (Efficacy measures how many vaccinated people contract COVID-19 compared with how many infections occur in the placebo or control group. Put another way, it represents the proportion of COVID-19 infections that could be prevented by vaccination).

… “I think the Johnson and Johnson (Janssen) one had much better clinical endpoints in the trials … there was a pretty low bar for establishing efficacy in the other trials,” she says.

Share